KRON - Kronos Bio gains as CEO buys over $2 million worth of shares

Cancer-focused clinical-stage biotech Kronos Bio (NASDAQ:KRON) is trading higher in the pre-market Friday after its President & Chief Executive Officer Norbert Bischofberger disclosed the purchase of about $2.3 million worth of company shares. Bischofberger made the purchase in three separate transactions this week, according to an SEC filing submitted on Thursday. The acquisition of 597,129 Kronos (KRON) shares at prices ranging from $3.72 to $3.83 has increased his stake in the company by ~11%. The insider transaction comes at a time when the company shares are trading over ~85% lower than the level a year ago, as shown in this graph.   San Mateo, California-based Kronos (KRON) is on track to announce additional Phase 1 data, along with the recommended Phase 2 dose for its cancer candidate KB-0742 in 4Q 2022.

For further details see:

Kronos Bio gains as CEO buys over $2 million worth of shares